NervGen Pharma Corp. (NGEN.V)
CAD 2.46
(-7.17%)
CAD 2.46
(-7.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -145 Thousand CAD | -25.96% |
| 2022 | -115.11 Thousand CAD | -170.06% |
| 2021 | -42.62 Thousand CAD | -7.52% |
| 2020 | -39.64 Thousand CAD | -3.73% |
| 2019 | -38.22 Thousand CAD | -93.4% |
| 2018 | -19.76 Thousand CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -38.3 Thousand CAD | 0.82% |
| 2024 Q2 | -15.02 Thousand CAD | 60.77% |
| 2023 Q2 | -34.99 Thousand CAD | -0.7% |
| 2023 Q1 | -34.75 Thousand CAD | 0.0% |
| 2023 FY | -145 Thousand CAD | -25.96% |
| 2023 Q4 | -38.62 Thousand CAD | -5.45% |
| 2023 Q3 | -36.62 Thousand CAD | -4.65% |
| 2022 Q1 | -11.38 Thousand CAD | -1.57% |
| 2022 FY | -115.11 Thousand CAD | -170.06% |
| 2022 Q4 | -34.75 Thousand CAD | -0.0% |
| 2022 Q3 | -34.75 Thousand CAD | -1.55% |
| 2022 Q2 | -34.22 Thousand CAD | -200.61% |
| 2021 FY | -42.62 Thousand CAD | -7.52% |
| 2021 Q4 | -11.2 Thousand CAD | -3.15% |
| 2021 Q3 | -10.86 Thousand CAD | -2.8% |
| 2021 Q2 | -10.57 Thousand CAD | -5.88% |
| 2021 Q1 | -9983.00 CAD | 0.0% |
| 2020 Q3 | - CAD | 0.0% |
| 2020 FY | -39.64 Thousand CAD | -3.73% |
| 2020 Q1 | - CAD | 0.0% |
| 2020 Q2 | - CAD | 0.0% |
| 2020 Q4 | - CAD | 0.0% |
| 2019 Q4 | - CAD | 0.0% |
| 2019 Q2 | - CAD | 0.0% |
| 2019 Q1 | - CAD | 0.0% |
| 2019 Q3 | - CAD | 0.0% |
| 2019 FY | -38.22 Thousand CAD | -93.4% |
| 2018 Q2 | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 FY | -19.76 Thousand CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arch Biopartners Inc. | -128.99 Thousand CAD | -12.412% |
| Covalon Technologies Ltd. | 14.36 Million CAD | 101.01% |
| Hemostemix Inc. | -223.00 CAD | -64923.767% |
| Universal Ibogaine Inc. | 1.07 Million CAD | 113.542% |
| Kane Biotech Inc. | 109.47 Thousand CAD | 232.459% |
| MedMira Inc. | -434.91 Thousand CAD | 66.659% |
| Marvel Biosciences Corp. | -887.51 Thousand CAD | 83.662% |
| XORTX Therapeutics Inc. | -188.54 Thousand CAD | 23.093% |